Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma

By Zdzalik Daria   Dymek Barbara   Grygielewicz Paulina   Gunerka Pawel   Bujak Anna   Lamparska-Przybysz Monika   Wieczorek Maciej   Dzwonek Karolina  

Journal of Cancer Research and Clinical Oncology, Vol. 140, Iss. 4, 2014-04 ,pp. : 589-598

Springer Publishing Company

Access to resources Recommend Favorite

Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report

By                  

Oncology Letters, Vol. 9, Iss. 4, 2015-01 ,pp. : 1537-1540

Spandidos Publications

Access to resources Recommend Favorite

EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 11, Iss. 4, 2016-11 ,pp. : 393-400

Bentham Science Publishers

Access to resources Recommend Favorite

The dichloromethane extract of the ethnomedicinal plant Neurolaena lobata inhibits NPM/ALK expression which is causal for anaplastic large cell lymphomagenesis

By                                        

International Journal of Oncology, Vol. 42, Iss. 1, 2013-01 ,pp. : 338-348

Spandidos Publications

Access to resources Recommend Favorite

Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell lung cancer tissues

By                        

Experimental and Therapeutic Medicine, Vol. 9, Iss. 6, 2015-01 ,pp. : 2151-2154

Spandidos Publications

Access to resources Recommend Favorite